Skip to main content

DexCom Inc. (DXCM) Stock

DexCom Inc. Stock Details, Movements and Public Alerts

Stock Details

DexCom Inc. (DXCM), a prominent company in the healthcare sector within the medical devices industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $68.36. Over the past 52 weeks, it has ranged between $57.52 and $93.25. This places the current price at 73.3% of its 52-week high and 18.8% above its 52-week low. Recent trading volume was recorded at 46,412. The 14-day Relative Strength Index (RSI) stands at 32.66, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $75.66 by 9.65%. Similarly, it is below its 200-day moving average of $79.30 by 13.80%. The MACD histogram is -0.10, indicating bearish momentum (MACD Line: -3.09, Signal Line: -2.99). The International Securities Identification Number (ISIN) for this stock is US2521311074.

52-Week Range

$93.25 - $57.52

-26.69% from high · +18.85% from low

Avg Daily Volume

6,727,459

20-day average

100-day avg: 4,183,833

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

47.22

Above market average

Forward P/E

25.64

Earnings expected to grow

PEG Ratio

0.85

Potentially undervalued

Price to Book

10.13

EV/EBITDA

24.74

EPS (TTM)

$1.42

Price to Sales

6.11

Beta

1.48

Similar volatility to market

How is DXCM valued relative to its earnings and growth?
DexCom Inc. trades at a P/E ratio of 47.22, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 25.64 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.85 suggests the stock may be undervalued relative to its growth rate.
What is DXCM's risk profile compared to the market?
With a beta of 1.48, DexCom Inc. is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 10.13 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

13.30%

Operating Margin

18.40%

EBITDA

$923.30M

Return on Equity

22.80%

Return on Assets

6.08%

Revenue Growth (YoY)

15.20%

Earnings Growth (YoY)

27.40%

How profitable and efficient is DXCM's business model?
DexCom Inc. achieves a profit margin of 13.30%, meaning it retains $13.30 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 18.40% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 22.80% and ROA at 6.08%, the company generates strong returns on invested capital.
What are DXCM's recent growth trends?
DexCom Inc.'s revenue grew by 15.20% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 27.40% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against MEDICAL DEVICES industry averages for proper context.

Company Size & Market

Market Cap

$26.3B

Revenue (TTM)

$4.30B

Revenue/Share (TTM)

$10.97

Shares Outstanding

392.15M

Book Value/Share

$6.56

Asset Type

Common Stock

What is DXCM's market capitalization and position?
DexCom Inc. has a market capitalization of $26.3B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 392.15M shares outstanding, the company's ownership is relatively concentrated. As a participant in the MEDICAL DEVICES industry, it competes with other firms in this sector.
How does DXCM's price compare to its book value?
DexCom Inc.'s book value per share is $6.56, while the current stock price is $68.36, resulting in a price-to-book (P/B) ratio of 10.42. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$100.54

47.07% upside potential

Analyst Recommendations

Strong Buy

4

Buy

19

Hold

4

Sell

0

Strong Sell

0

How reliable are analyst predictions for DXCM?
27 analysts cover DXCM with 85% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $100.54 implies 47.1% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on DXCM?
Current analyst recommendations:4 Strong Buy, 19 Buy, 4 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 6, 2025, 06:54 PM

Technical Indicators

RSI (14-day)

32.66

Neutral

50-Day Moving Average

$75.66

-9.65% below MA-50

200-Day Moving Average

$79.30

-13.80% below MA-200

MACD Line

-3.09

MACD Signal

-2.99

MACD Histogram

-0.10

Bearish

What does DXCM's RSI value tell investors?
The RSI (Relative Strength Index) for DXCM is currently 32.66, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
How should traders interpret DXCM's MACD and moving average crossovers?
MACD analysis shows the MACD line at -3.09 below the signal line at -2.99, with histogram at -0.10. This bearish crossover indicates downward pressure. The 50-day MA ($75.66) is below the 200-day MA ($79.30), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Oct 8, 2025, 12:56 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for DXCM and get notified when the price changes.

Stay Ahead of the Market with DexCom Inc. Alerts

Set up price alerts for DexCom Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.